Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lisata Therapeutics, Inc (LSTA) Fair Value & Analysis

Healthcare · US · Market cap $32.1M

Price$3.44
Fair Value$3.98
Upside+15.7%
Quality93/100
Evidence: Low Range $1.92 – $6.28

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Lisata Therapeutics, Inc (LSTA) currently trades at $3.44, while our model-based Fair Value estimate is $3.98 — implying the stock looks roughly 15.7% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Lisata Therapeutics, Inc (LSTA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.98 versus a price of $3.44 — about +16% (undervalued). Model-based estimate, not financial advice.
What is the fair value of LSTA?
Our 21-model fair value for Lisata Therapeutics, Inc is $3.98 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.44.
What is the quality score of LSTA?
Lisata Therapeutics, Inc has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.